Holycross Cancer Center
Holycross Cancer Center
Trznadel A.,Municipal Family Assistance Center in Kielce |
Grzybek P.,Holycross Cancer Center |
Grzybek P.,Jan Kochanowski University
Polish Annals of Medicine | Year: 2016
Introduction: The increase in cancer incidence and mortality calls for a search of effective methods to improve patient's quality of life and well-being. Aim: The aim of this article is to present a case study that examined the application of eye movement desensitization and reprocessing (EMDR) therapy for a cancer patient. Case study: The patient (Mrs B) was diagnosed with malignant neoplasm of the breast; and during her stay at Holycross Cancer Centre she decided to undergo EMDR therapy in order to deal with pre-existing feelings of helplessness and anxiety. She attended three 90-min sessions, all performed according to the EMDR therapy standard protocol. Furthermore, Mrs B's level of distress was measured using the distress thermometer and she filled in a problem checklist before and after the treatment. The target event, the worst image as well as positive and negative cognition were identified. Also, the validity of cognition (VOC) and subjective units of disturbance were measured before and after the therapy. Furthermore, the patient reported negative body sensations. Then, desensitization phase followed. Results: The results of the therapy were: significantly lower level of distress and less problems reported. The patient did not feel any negative emotions or physical sensations and her VOC increased too. Discussion: The results are discussed in relation to other studies and future directions for the research are suggested. Conclusions: This case suggests possible advantages of EMDR therapy, demonstrating an improvement in patient's well-being in a short time. © 2016 Warmińsko-Mazurska Izba Lekarska w Olsztynie.
Wolowiec P.,Holycross Cancer Center |
Kukolowicz P.F.,Center of Oncology of Poland
Radiation Measurements | Year: 2016
Introduction The required overall uncertainty in dose delivery in modern radiotherapy is 3.5% of a prescribed dose (one standard deviation). In vivo dosimetry is the simple method in dose delivery control. In this work we present our results concerning the precision of dose measurement with Gafchromic EBT films used within the dose range measured in the in vivo dosimetry of photon external beam radiation therapy. Materials and methods The rectangular pieces of Gafchromic EBT films of 1 cm × 2 cm were prepared. They were prepared from three different films from two batches. For each film four sets of samples consisting of 18 pieces were made. Each set of films was exposed perpendicularly to 6 MV photon beams at several dose levels from 2 cGy to 190 cGy. The net optical density was read with the flatbed document scanner Epson Expression 10000 XL and the ImageJ software. The calibration curves for each set of Gafchromic EBT samples were obtained. The mathematical formulae describing the calibration curve was fitted to the measurements results. Four different calibration procedures were analyzed based on one or four sets of samples and with or without use of image filtration (median filter). Two sources of uncertainty were analyzed separately: the calibration curve measurements, and the precision of formulae fitting. Results For the protocol described in this paper, the overall dose measurement uncertainty of less than 2% (one standard deviation) for doses of about 25 cGy and higher was found for calibration procedure based on four sets of film samples with image filtration, and less than 3% for calibration procedure based on one set of film samples with image filtration. For two films from the same batch almost identical calibration curves were obtained. It allows to use one calibration curve for all films from the same batch. There were larger differences for films from two different batches. Conclusions The Gafchromic EBT films have sufficient accuracy for dose measurements above 20 cGy and may be an interesting alternative for the semiconductor or thermoluminescent detectors as an in vivo dosimeter. Contrary to these detectors Gafchromic EBT films are transparent for radiation. © 2016 Elsevier Ltd
Lasota J.,U.S. National Cancer Institute |
Wasag B.,Medical University of Gdańsk |
Wang Z.-F.,U.S. National Cancer Institute |
Felisiak-Golabek A.,U.S. National Cancer Institute |
And 4 more authors.
American Journal of Surgical Pathology | Year: 2014
Recently BRAF V600E mutant-specific antibody (clone VE1) became available to immunohistochemically pinpoint the occurrence of these BRAF-mutant proteins in different tumors, such as colon carcinoma. Detection of BRAF mutations is important for the accurate application of targeted therapy against BRAF serine-threonine kinase activation. In this study, we evaluated 113 colon carcinomas including 95 primary and 27 metastatic tumors with the VE1 antibody using Leica Bond-Max automated immunohistochemistry. To ensure comprehensive BRAF V600E mutation detection, all cases were evaluated using 4 molecular methods (Sanger sequencing, the Cobas 4800 BRAF V600 Mutation Test, BRAF V600 allele-specific polymerase chain reaction, and BRAF V600 quantitative polymerase chain reaction) with nearly 100% concordance. Molecular and immunohistochemical studies were blinded. Furthermore, all cases were evaluated for KRAS and NRAS mutations as parameters mutually exclusive with BRAF mutations offering parallel evidence for BRAF mutation status. Strong to moderate VE1 positivity was seen in 34 tumors. Twelve colon carcinomas showed weak VE1 immunohistochemical staining, and 67 were entirely negative. An identical c.1799T>A single nucleotide substitution leading to the BRAF V600E mutation was identified in 27 of 113 (24%) colon carcinomas. A majority of BRAF-mutant tumors were located in the right side of the colon and had mismatch-repair deficiency. V600E mutation-negative carcinomas were more often sigmoid tumors and usually showed intact mismatch-repair proteins and KRAS or NRAS mutations. The sensitivity and specificity of positive results (strong to moderate staining) of VE1 immunohistochemistry were 85% and 68%, respectively. If any positivity would be considered, then the specificity declined to 51% with no significant improvement of sensitivity. Therefore, only strong positivity should be considered when using the VE1 antibody and Leica Bond-Max automated immunohistochemistry with these parameters. Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis. © 2014 by Lippincott Williams and Wilkins.
Peczkowska M.,Institute of Cardiology |
Kowalska A.,Holycross Cancer Center |
Sygut J.,Holycross Cancer Center |
Waligorski D.,Holycross Cancer Center |
And 5 more authors.
Clinical Endocrinology | Year: 2013
Background Phaeochromocytoma (PCC) and paraganglioma (PGL) can occur sporadically or as a part of familial cancer syndromes. Red flags of hereditary syndromes are young age and multifocal tumours. We hypothesized that such patients are candidates for further molecular diagnosis in case of normal results in 'classical' genes. Material and methods We selected patients with PCC/PGL under the age of 40 and/or with multiple tumours. First, we tested the genes RET, VHL, NF1, SDHB, SDHC and SDHD. Patients without mutations in these genes were tested for mutations in MAX, TMEM127 and SDHAF2. Results In 153 patients included, mutations were detected in the classical genes in 72 patients (47%) [RET-22 (14%), VHL-13 (9%), NF1-3 (2%), SDHB-13 (9%), SDHC-3 (2%), SDHD-16 (11%), SDHB large deletions- 2 (1%)]. One patient with MAXc.223C>T (p.R75X) mutation was detected. It was a male with bilateral, metachronous phaeochromocytomas diagnosed in 36 and 40 years of age. Remarkably, he showed in the period before the MAX gene was detected, a RET p. Y791F variant. During 10-year follow-up, we did not find any thyroid abnormalities. LOH examination of tumour tissue showed somatic loss of the wild-type allele of MAX. Conclusion Analysis of the MAX gene should be performed in selected patients, especially those with bilateral adrenal phaeochromocytoma in whom mutations of the classical genes are absent. Our study provides with further support that Y791F RET is a polymorphism. © 2013 John Wiley & Sons Ltd.
Stelmach-Goldys A.,Holycross Cancer Center |
Czarkowska-Paczek B.,Medical University of Warsaw |
Wyczalkowska-Tomasik A.,Medical University of Warsaw |
Paczek L.,Medical University of Warsaw
European Journal of Haematology | Year: 2015
Objectives: Monoclonal gammopathy of undetermined significance (MGUS) occurs without other symptoms, although monoclonal proteins can cause kidney injuries. Here, we assessed kidney function and identified the best follow-up parameters in patients with MGUS without kidney damage symptoms. Methodology: Forty-six patients with MGUS were included in the study group. The control group (CRT, n = 23) consisted of healthy subjects matched for age and sex. Serum cystatin C was determined using an immunonephelometric method, serum and urine neutrophil gelatinase-associated lipocalin (NGAL) was measured with an immunoenzymatic method, and cathepsin B activity was determined fluorometrically. Results: Serum cystatin C and urine NGAL were higher, and serum NGAL was lower in MGUS patients compared with CRT. Neither serum cystatin C, nor serum or urine NGAL, correlated with the biomarkers of MGUS. The serum activity of cathepsin B did not differ between groups and did not correlate with serum cystatin C. Serum cystatin C correlated with serum creatinine, while serum NGAL did not correlate with serum creatinine or cystatin C. The estimated glomerular filtration rates (eGFRs) in MGUS were within normal range and correlated with serum cystatin C. The strongest correlation was observed for CKD-EPI. Seven patients presented with albuminuria >30 mg/day. There was a correlation between albuminuria in this group and λ free light chains. Conclusions: The kidney function in MGUS patients is impaired, although there are no clinical and standard laboratory test manifestations. Cystatin C and urine, but not serum, NGAL should be considered markers for kidney injury. CKD-EPI is recommended for eGFR assessment. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Kepka L.,Oncology and Radiotherapy Institute |
Bujko K.,Oncology and Radiotherapy Institute |
Orlowski T.M.,Institute of Tuberculosis and Lung Diseases |
Jagiello R.,Institute of Tuberculosis and Lung Diseases |
And 4 more authors.
Radiotherapy and Oncology | Year: 2011
Aim: To prospectively assess the cardiopulmonary morbidity and quality of life in patients with non-small cell lung cancer (NSCLC) treated with postoperative radiotherapy (PORT) in comparison to those not receiving PORT. Materials and methods: From 2003 to 2007, 291 patients entered the study; 171 pN2 patients received 3D-planned PORT (PORT group), 120 pN1 patients (non-PORT group) did not. One month after surgery, all patients completed EORTC QLQ C-30 questionnaire and had pulmonary function tests (PFT); cardiopulmonary symptoms were assessed by modified LENT-SOM scale. Two years later, disease-free patients repeated the same examinations. The differences between baseline values and values recorded at two years in QLQ, LENT-SOM and the PFT of the two groups were compared. Results: In the whole cohort, the rate of non-cancer related deaths was 5.3% and 5.0% in PORT and non-PORT group, respectively. Ninety-five patients (47 - PORT group, 48 - non-PORT group) were included into the final analysis. The differences in the QLQ and cardiopulmonary function (LENT/SOM, PFT) between both groups were insignificant. The forced expiratory volume in one second was on average 12.2% and 1.3% better in the PORT and the non-PORT group, respectively, p = 0.2. Conclusions: Our findings support the hypothesis about insignificant morbidity of 3D-planned PORT. © 2010 Elsevier Ireland Ltd. All rights reserved.
Mysliwiec J.,Medical University of Bialystok |
Palyga I.,Holycross Cancer Center |
Kosciuszko M.,Medical University of Bialystok |
Kowalska A.,Holycross Cancer Center |
Gorska M.,Medical University of Bialystok
Hormone and Metabolic Research | Year: 2012
The aim of the study was to assess the usefulness of circulating chemokines CXCL9 and CXCL10 measurements as surrogate markers of GO activity and as a guideline in therapeutic decision-making. Forty-two individuals were divided into 4 groups: 1. 15 euthyroid patients with clinical symptoms of orbitopathy (GO) who underwent corticosteroid therapy consisting of intravenous infusions of methylprednisolone (MP) and teleradiotherapy (TR); 2. 10 patients with hyperthyroid GD (Gtx); 3. 10 patients with GD in euthyreosis (Geu); and 4. 7 healthy volunteers age and sex-matched to groups 1-3. The serum samples were collected 24h before MP, 24h after first dose of MP, before TR and at the end of therapy. Serum CXCL9 and CXCL10 were determined by ELISA and TSH-Rab by RIA. There were significant reductions in CXCL9 and CXCL10 serum concentrations during CS and TR treatment as compared both to control group and to basal values in GO patients. Moreover, CXCL9 concentration was significantly diminished in comparison to controls in GO patients who were identified later as corticosteroid-respondent (p<0.001). In this latter group of patients, CXCL9 was also found to be significantly reduced 24h after first dose of MP as compared to non-respondents (p<0.02). The high-degree positive correlation between CXCL9 and CXCL10 was found (R=0.8; p<0.001). Our results suggest that the increased concentrations of CXCL9 (and CXCL10), at least in part, reflect the activity of orbital inflammation and therefore these chemokines could serve as a guideline in therapeutic decision-making in patients with Graves' orbitopathy. © Georg Thieme Verlag KG · Stuttgart.
Walczyk A.,Holycross Cancer Center |
Kowalska A.,Holycross Cancer Center |
Kowalik A.,Holycross Cancer Center |
Sygut J.,The Surgical Center |
And 5 more authors.
Clinical Endocrinology | Year: 2014
Context An activating mutation in the gene BRAF has been correlated with poorer prognosis and more aggressive clinical course in papillary thyroid carcinoma (PTC). We therefore hypothesized that the good prognosis, high 5-year disease-free rate and high survival rate of patients with less aggressive papillary thyroid microcarcinoma (pT1aNo-x) would be associated with a lower incidence of the BRAFV600E mutation. Objectives To evaluate the frequency of the activating mutation BRAFV600E in low-risk papillary thyroid microcarcinoma (pT1aNo-x at the moment of diagnosis) and the association of the mutation with the clinical outcome in a retrospective analysis. Study Design BRAFV600E was characterized in 113 PTC patients diagnosed with pT1aNo-x (one PTC focus with a diameter <1 cm, without lymph node or distant metastases according to IUCC/AJCC TNM staging system 2010). Genotyping was performed on DNA extracted from thyroid tumour tissue using direct capillary sequencing, and allele-specific amplification PCR was used to resolve equivocal results. Retrospective analysis of the clinical course of PTC was then correlated with BRAF status in the primary tumour tissue. Results The BRAF V600E mutation was detected in 78 of the 113 pT1aNo-x patients (69·0%). We observed no persistence, locoregional recurrence, lymph node or distant metastases or deaths in the study group during the 12-year study (January 2001 to December 2012). Conclusions The presence of the activating BRAFV600E mutation in a significant percentage of papillary thyroid microcarcinoma indicates that further analyses are required to verify its usefulness as a predictor of clinical outcome in PTC. In this study, there was no correlation between BRAF-positive primary focus of papillary microcarcinoma and more aggressive or recurrent disease. © 2013 John Wiley & Sons Ltd.
Lewandowski K.C.,Medical University of Lódz |
Gasior-Perczak D.,Holycross Cancer Center |
Kowalska A.,Holycross Cancer Center |
Lewinski A.,Medical University of Lódz
Gynecological Endocrinology | Year: 2014
Macroprolactin may cause elevation of prolactin (PRL) concentrations measured by standard assays. In our study, we assessed the prevalence of pituitary lesions in women with macroprolactinaemia and either oligomenorrhoea or secondary amenorrhoea. Pituitary MRI scans were performed in 61 women aged 31.0±6.7years (mean±SD), with raised PRL concentrations due to macroprolactinaemia, detected by 25% polyethylene glycol (PEG) precipitation method (PRL recovery <40%). After PEG precipitation of macroprolactin, free PRL concentrations were still raised in 36 (59%) women. Microadenomas were detected in 10 patients out of 61 (16.4%), with raised free PRL in 9 of these cases, while macroadenomas were detected in 4 out of 61 (6.6%) women, all of whom also had raised free PRL. In case of coexistence of macroprolactinaemia and raised free PRL after PEG precipitation of macroprolactin, the chance of finding of either a micro- or a macroadenoma was 36% (13 cases out of 36). We conclude that hyperprolactinaemia and macroprolactinaemia may coexist in the same patient. Furthermore, if free PRL is raised after PEG precipitation of macroprolactin, then the chance of finding either a pituitary micro- or macroadenoma in women with oligo-/amenorrhoea is over 30%. Therefore pituitary magnetic resonance imaging is mandatory in all such cases. © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted.
Gozdz S.,Holycross Cancer Center
Roczniki Państwowego Zakładu Higieny | Year: 2013
Premature mortality in younger age groups influences the society as far as social and economic aspects are concerned. Therefore, it is important to come up with a tool which will allow to assess them, and will enable to implement only these health care measures that bring tangible benefits. That is the reason for introducing PYLL rate (PYLL - potential years of life lost), which is an addition to the analysis of premature mortality as it includes the number of deaths due to a particular cause and the age at death. The purpose of this study was to analyse the level and trends of PYLL rate according to death causes in years 2002 -2010 in Swietokrzyskie Province. The material for the analysis was the information from the Central Statistical Office on the number of deaths due to all causes registered among the inhabitants of Swiytokrzyskie Province in years 2002-2010. Causes of death were coded according to the 10th revision of the International Classification of Diseases. The analysis of premature mortality was carried out with the use of PYLL rate. PYLL rate was calculated according to the method proposed by Romeder, according to which the premature mortality was defined as death before the age of 70. The analysis of time trends of PYLL rate and the APC (annual percent change) of the PYLL rate were calculated using jointpoint model as well as the Jointpoint Regression Program (Version 4.0.1 - January 2013). In men, in years 2002 - 2007 PYLL rate increased by 1.5% per year (p<0.05). From year 2007 the trend went downward and PYLL rate decreased on average by 3.1% per year till year 2010. External causes of death, cardiovascular diseases and cancers in years 2002 - 2010 were the reason for almost 74.0% PYLL in men. In year 2010 PYLL rate due to all death causes amounted to 8913.8/105 and was three times higher than in women (2975.5/10(5)). In women, however, during the analysed period PYLL rate did not change significantly, and was dominated by cancers, cardiovascular diseases and external death causes. Similarly to men, those three groups of death causes were responsible for an average 76.0% PYLL. The analysis of the causes of premature mortality in Swietokrzyskie Province shows that in the majority of cases it is due to preventable deaths, which calls for the necessity of more intensive measures in primary and secondary prevention as well as the improvement in treatment standards, mainly of cardiovascular diseases, cancers, injuries and accidents.